Quarterly injection stops bone loss

An intravenous formulation of Roche's bisphosphonate Bonviva (ibandronic acid 3mg/mL) has been licensed for the treatment of postmenopausal osteoporosis.

Administered every three months by intravenous injection over 15-30 seconds, Bonviva IV provides long term protection against bone loss and reduces the risk of vertebral fractures. The intravenous formulation is particularly suitable for those women who find it difficult to follow the strict dosage regimen required for the oral formulation.

A two-year clinical study comparing the efficacy, safety and tolerability of the intravenous formulation with the oral formulation found that the intravenous formulation produced a greater increase in lumbar spine and hip bone mineral density than the oral formulation, was equally well tolerated and had a similar incidence of adverse reactions.

Bonviva IV is presented as a prefilled syringe costing £80.00.

Further information: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW. Tel: (01707) 366000.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more